Compare ARVN & UHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | UHT |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.2M | 595.1M |
| IPO Year | 2018 | 1995 |
| Metric | ARVN | UHT |
|---|---|---|
| Price | $8.01 | $43.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 1 |
| Target Price | $15.05 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 647.9K | 140.0K |
| Earning Date | 05-04-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 7.33% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $262,600,000.00 | $99,190,000.00 |
| Revenue This Year | N/A | $2.12 |
| Revenue Next Year | N/A | $2.94 |
| P/E Ratio | ★ N/A | $120.25 |
| Revenue Growth | N/A | ★ 0.18 |
| 52 Week Low | $6.06 | $35.26 |
| 52 Week High | $14.22 | $46.30 |
| Indicator | ARVN | UHT |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 57.08 |
| Support Level | $7.90 | $42.17 |
| Resistance Level | $8.90 | $44.46 |
| Average True Range (ATR) | 0.31 | 0.95 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 6.00 | 54.39 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.